Summit Therapeutics said its Ivonescimab treatment reduced the risk of disease progression or death by 49% compared with the ...

Atea has struggled to demonstrate bemnifosbuvir’s COVID potential in the past, including in a phase 2 trial back in the midst ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year.

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...

Seres Therapeutics' financial moves, potential drug developments, and investment appeal for speculative buyers in the biotech ...

The first, called nirmatrelvir, blocks the activity of an enzyme the COVID-19 virus needs to copy itself, also called repl ...

Merck (MRK) and Daiichi Sankyo (DSNKY) announce early results from a Phase 2 trial of lung cancer drug I-DXd, an antibody ...

Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 ...

Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...

PORTLAND, IL, UNITED STATES, September 11, 2024 /EINPresswire / -- The growth of the global liver <a target=_blank href= ...

Ebola virus disease kills more than half of people infected. Since the disease is transmitted via close human contact, ...